NCT02294292View on ClinicalTrials.gov

Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality

NACompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

July 1, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Diastolic DysfunctionChronic Liver Disease
Interventions
DRUG

Carvedilol

Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.

DRUG

Ivabradine

"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"

PROCEDURE

Endoscopic Variceal Ligation

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT02294292 - Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality | Biotech Hunter | Biotech Hunter